What's new

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 27, Status: Authorised

Jun 11, 2025 - 13:45
 0
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 27, Status: Authorised
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 27, Status: Authorised
Read More

Tags:

Previous Article

EMEA-003563-PIP01-23

Next Article

EMEA-003390-PIP01-23

Related Posts

Human medicines European public assessment report (EPAR): Korjuny, catumaxomab, Date of authorisation: 10/02/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

May 20, 2025  0

Human medicines European public assessment report (EPAR): Maapliv, amino acids, Status: Opinion

Human medicines European public assessment report (EPAR...

May 23, 2025  0

EMA workshop on primary efficacy endpoints for antivirals and mAbs intended for the treatment of COVID-19 and Influenza, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 June 2025, 13:00 (CEST) to 6 June 2025, 17:00 (CEST)

EMA workshop on primary efficacy endpoints for antivira...

May 12, 2025  0